Inhaled drug shows promise for rare lung disease combination

A therapeutic principle rooted in decades of pulmonary vascular research is entering a new stage of clinical development. The investigational inhaled drug mosliciguat, a soluble guanylate cyclase (sGC) activator, has produced ...

page 5 from 40